Literature DB >> 29510204

Strategic drug analysis in fed-state gastric biorelevant media based on drug physicochemical properties.

Fotios Baxevanis1, Jesse Kuiper2, Nikoletta Fotaki3.   

Abstract

Milk-based media such as the Fed State Simulated Gastric Fluid (FeSSGF) are commonly used in order to simulate the in vivo properties of the fed state stomach. Due to the lack of a specific guideline for standardised sample clean-up in these media, the aim of the current study was to develop an optimum protocol for the extraction and quantification of drugs from the fed state gastric medium based on the APIs' physicochemical properties (lipophilicity, ionisation, aqueous solubility and protein binding). Two different extraction techniques, protein precipitation (PP) and solid phase extraction (SPE) were assessed. A pilot study in six model drugs was performed, with tests using seven different protein precipitation reagents at four different medium:reagent ratios and two drug concentrations as well as different solid phase extraction cartridges and elution protocols. % recovery was analysed using partial least squares (PLS) regression so as to determine the physicochemical parameters affecting the drug percentage recovered. For protein precipitation protocols, drug concentration, selection of protein precipitation reagent and ratio added to the medium significantly affected drug % recovery from FeSSGF (p < 0.05). The same applied for the selection of elution solvent and cartridge type for solid phase extraction. Optimum protocols using MeOH, ΑCN and 10% w/v TCA at a 1:2 FeSSGF:reagent ratio were effective to a larger group of drugs of a wide range of lipophilicity and ionisation, with ΑCN being the most effective in the whole range of log P values (-0.56 to 8.81). Solid phase extraction was proven to be effective for compounds of poor to moderate lipophilicity (log P < 4), with extremely hydrophobic compounds demonstrating lower % recovery values (down to 10% recovery). PLS demonstrated that only for 10% w/v TCA (protein precipitation) and HLB (solid phase extraction) can the effect of key drug physicochemical properties on the final amount of drug recovered be accurately predicted.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biorelevantmedia; Drug analysis; Fed state; Physicochemical properties; Protein precipitation; Solid phase extraction

Mesh:

Substances:

Year:  2018        PMID: 29510204     DOI: 10.1016/j.ejpb.2018.03.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.

Authors:  Anna C Van der Vossen; Lidwien M Hanff; Arnold G Vulto; Nikoletta Fotaki
Journal:  Br J Clin Pharmacol       Date:  2019-06-18       Impact factor: 4.335

2.  Development and Validation of an HPLC-UV Method for the Dissolution Studies of 3D-Printed Paracetamol Formulations in Milk-Containing Simulated Gastrointestinal Media.

Authors:  Natalia Manousi; Christina Karavasili; Dimitrios G Fatouros; Paraskevas D Tzanavaras; Constantinos K Zacharis
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-16

3.  Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis.

Authors:  Mariana Guimarães; Anil Maharaj; Andrea Edginton; Maria Vertzoni; Nikoletta Fotaki
Journal:  Pharmaceutics       Date:  2022-02-04       Impact factor: 6.321

4.  Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.

Authors:  Mariana Guimarães; Pascal Somville; Maria Vertzoni; Nikoletta Fotaki
Journal:  AAPS J       Date:  2022-01-10       Impact factor: 4.009

5.  Evaluating pediatric and adult simulated fluids solubility: Abraham solvation parameters and multivariate analysis.

Authors:  Mariana Guimarães; Martin Kuentz; Maria Vertzoni; Nikoletta Fotaki
Journal:  Pharm Res       Date:  2021-10-25       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.